Age |
54.4 ± 9.2 |
52.1 ± 8.4 |
55 ± 9.4 |
0.469 |
Gender
Female, n (%)
Male, n (%)
|
33 (94.3)
2 (5.7)
|
7 (100)
0 (0)
|
26 (92.9)
2 (7.1)
|
0.466
|
Asthma, n (%) |
5 (14.3) |
2 (28.6) |
3 (10.7) |
0.256 |
COPD, n (%) |
4 (11.4) |
0 (0) |
4 (14.3) |
0.562 |
DM, n (%) |
3 (8.6) |
0 (0) |
3 (10.7) |
0.365 |
HT, n (%) |
5 (14.3) |
1 (14.3) |
4 (14.3) |
1 |
CRF, n (%) |
1 (2.9) |
0 (0) |
1 (3.6) |
0.612 |
CAD |
1 (2.9) |
0 (0) |
1 (3.6) |
0.612 |
Hypothyroidism, n (%) |
2 (5.7) |
0 (0) |
2 (7.1) |
0.466 |
RA |
1 (2.9) |
0 (0) |
1 (3.6) |
0.612 |
Alergic rhinitis,n (%) |
1 (2.9) |
0 (0) |
1 (3.6) |
0.612 |
ILD, n (%) |
1 (2.9) |
0 (0) |
1 (3.6) |
0.612 |
Multiple Sclerosis, n (%) |
1 (2.9) |
1 (14.3) |
0 (0) |
0.200 |
Hydroxychloroquine, n (%) |
31 (88.6) |
4 (57.1) |
27 (96.4) |
0.019 |
Steroid, n (%) |
24 (68.6) |
5 (71.4) |
19 (67.9) |
0.856 |
MTX, n (%) |
2 (5.7) |
2 (28.6) |
0 (0) |
0.035 |
Azathioprine, n (%) |
8 (22.9) |
3 (42.9) |
5 (17.9) |
0.312 |
Colchicine, n (%) |
2 (5.7) |
2 (28.6) |
0 (0) |
0.035 |
Dry cough, n (%) |
6 (17.1) |
2 (28.6) |
4 (14.3) |
0.576 |
Effort dyspnea, n (%) |
8 (22.9) |
2 (28.6) |
6 (21.4) |
0.648 |
Raynaud phenomenon, n (%) |
8 (22,8) |
2 (28,5) |
6 (21,4) |
0.644 |
Duration of illness, median (min-max) |
74 (1-180) |
80 (2-120) |
32
(1-180) |
0.214 |